This company has been marked as potentially delisted and may not be actively trading.

Tourmaline Bio (TRML) Stock Forecast & Price Target

Get the Latest News and Ratings for TRML and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Tourmaline Bio and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TRML Analyst Ratings Over Time

Type	Current Forecast 5/6/25 to 5/6/26	1 Month Ago 4/6/25 to 4/6/26	3 Months Ago 2/5/25 to 2/5/26	1 Year Ago 5/6/24 to 5/6/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	1 Buy rating(s)	1 Buy rating(s)	7 Buy rating(s)
Hold	9 Hold rating(s)	9 Hold rating(s)	9 Hold rating(s)	0 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$47.94	$47.94	$47.94	$49.33
Forecasted Upside	-0.07% Downside	-0.07% Downside	-0.07% Downside	239.29% Upside
Consensus Rating	Hold	Hold	Hold	Buy

TRML Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

TRML Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Tourmaline Bio Stock vs. The Competition

Type	Tourmaline Bio	Medical Companies	S&P 500
Consensus Rating Score	2.00	2.30	2.52
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	-0.07% Downside	938.23% Upside	14.75% Upside
News Sentiment Rating	Neutral News See Recent TRML News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
10/29/2025	Cantor Fitzgerald 5 of 5 stars	Josh Schimmer 5 of 5 stars	Reiterated Rating	Overweight
10/8/2025	Weiss Ratings Not Rated		Reiterated Rating	Sell (D-)
9/15/2025	BMO Capital Markets 4 of 5 stars	Kostas Biliouris 3 of 5 stars	Downgrade	Outperform ➝ Market Perform	$35.00 ➝ $48.00	+0.82%
9/11/2025	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yasmeen Rahimi Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$65.00 ➝ $48.00	+0.85%
9/10/2025	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robyn Karnauskas Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$63.00 ➝ $48.00	+0.76%
9/10/2025	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yatin Suneja Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$55.00 ➝ $48.00	+0.76%
9/10/2025	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yi Chen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$50.00 ➝ $48.00	+0.76%
9/10/2025	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Daniil Gataulin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$70.00 ➝ $48.00	+0.76%
9/9/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Roger Song Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$64.00 ➝ $47.50	-0.29%
9/9/2025	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rami Katkhuda Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Outperform ➝ Hold	$48.00	+0.76%

9/9/2025	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Laura Chico Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$48.00	+59.05%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 01:24 AM ET.

TRML Forecast - Frequently Asked Questions

: According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Tourmaline Bio is $47.94, with a high forecast of $48.00 and a low forecast of $47.50.
: 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tourmaline Bio in the last year. There is currently 1 sell rating, 9 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" TRML shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TRML, but not buy additional shares or sell existing shares.
: According to analysts, Tourmaline Bio's stock has a predicted downside of -0.07% based on their 12-month stock forecasts.
: Analysts like Tourmaline Bio less than other "medical" companies. The consensus rating score for Tourmaline Bio is 2.00 while the average consensus rating score for "medical" companies is 2.30. Learn more on how TRML compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Tourmaline Bio Recommendations

This page (NASDAQ:TRML) was last updated on 5/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.